A New Variant among Newcastle Disease Viruses Isolated in the Democratic Republic of the Congo in 2018 and 2019
Abstract
:1. Introduction
2. Materials and Methods
2.1. Sample Collection
2.2. Virus Isolation and Identification
2.3. Sequencing, Phylogenetic, and Genetic Analyses
2.4. Pathogenicity Assessment of NDV Isolates
2.5. Antigenic Characterization
2.6. Vaccine Potency Test
2.7. Ethical Statement
3. Results
3.1. Virus Isolation and Identification
3.2. Phylogenetic and Genetic Analyses
3.3. Pathogenicity of the DRC Isolates
3.4. Antigenic Characterization
3.5. Vaccine Potency against the Field Isolate
4. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- International Committee on Taxonomy of Viruses. ICTV Virus Taxonomy: 2019 Release. Available online: https://ictv.global/taxonomy (accessed on 3 September 2020).
- Lamb, R.A.; Parks, P.G. Paramyxoviridae. In Fields Virology, 6th ed.; Clinical Infection Diseases; Knipe, D.M., Howley, P.M., Eds.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2013; Volume I, pp. 957–995. [Google Scholar]
- Samson, A.C.R.; Levesley, I.; Russell, P.H. The 36K polypeptide synthesized in Newcastle disease virus-infected cells possesses properties predicted for the hypothesized ‘V’ protein. J. Gen. Virol. 1991, 72, 1709–1713. [Google Scholar] [CrossRef] [PubMed]
- Steward, M.; Vipond, I.B.; Millar, N.S.; Emmerson, P.T. RNA editing in Newcastle disease virus. J. Gen. Virol. 1993, 74, 2539–2547. [Google Scholar] [CrossRef] [PubMed]
- De Leeuw, O.; Peeters, B. Complete nucleotide sequence of Newcastle disease virus: Evidence for the existence of a new genus within the subfamily Paramyxovirinae. J. Gen. Virol. 1999, 80, 131–136. [Google Scholar] [CrossRef] [PubMed]
- Kim, D.; Martinez-Sobrido, L.; Choi, C.; Petroff, N.; García-Sastre, A.; Niewiesk, S.; Carsillo, T. Induction of type I interferon secretion through recombinant Newcastle disease virus expressing measles virus hemagglutinin stimulates antibody secretion in the presence of maternal antibodies. J. Virol. 2011, 85, 200–207. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Miller, P.J.; Estevez, C.; Yu, Q.; Suarez, D.L.; King, D.J. Comparison of viral shedding following vaccination with inactivated and live Newcastle disease vaccines formulated with wild-type and recombinant viruses. Avian Dis. 2009, 53, 39–49. [Google Scholar] [CrossRef] [PubMed]
- Dimitrov, K.M.; Abolnik, C.; Afonso, C.L.; Albina, E.; Bahl, J.; Berg, M.; Briand, F.-X.; Brown, I.H.; Choi, K.-S.; Chvala, I.; et al. Updated unified phylogenetic classification system and revised nomenclature for Newcastle disease virus. Infect. Genet. Evol. 2019, 74, 103917. [Google Scholar] [CrossRef] [PubMed]
- Alexander, D. Newcastle disease and other avian paramyxovirus. Rev. Sci. Tech. 2000, 19, 443–462. [Google Scholar] [CrossRef] [PubMed]
- Dimitrov, K.M.; Ramey, A.M.; Qiu, X.; Bahl, J.; Afonso, C.L. Temporal, geographic, and host distribution of avian paramyxovirus 1 (Newcastle disease virus). Infect. Genet. Evol. 2016, 39, 22–34. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nagai, Y.; Klenk, H.-D.; Rott, R. Proteolytic cleavage of the viral glycoproteins and its significance for the virulence of Newcastle disease virus. Virology 1976, 72, 494–508. [Google Scholar] [CrossRef]
- Dortmans, J.C.F.M.; Koch, G.; Rottier, P.J.M.; Peeters, B. Virulence of Newcastle disease virus: What is known so far? Vet. Res. 2011, 42, 122. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- African-Union, Interafrican Bureau for Animal Resources. Newcastle Disease 2011. Available online: www.au-ibar.org/2012-10-01-13./348-newcastle-disease (accessed on 15 October 2020).
- World Organization for Animal Health (OIE). Newcastle disease virus (Infection with Newcastle disease virus). In The OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals 2019; OIE: Paris, France, 2019; pp. 964–983. Available online: https://www.oie.int/standard-setting/terrestrial-manual/access-online/ (accessed on 10 October 2020).
- Kumar, S.; Stecher, G.; Tamura, K. MEGA7: Molecular evolutionary genetics analysis version 7.0 for bigger datasets. Mol. Biol. Evol. 2016, 33, 1870–1874. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nguyen, L.T.; Nishi, T.; Shichinohe, S.; Chu, D.-H.; Hiono, T.; Matsuno, K.; Okamatsu, M.; Kida, H.; Sakoda, Y. Selection of antigenic variants of an H5N1 highly pathogenic avian influenza virus in vaccinated chickens. Virology 2017, 510, 252–261. [Google Scholar] [CrossRef] [PubMed]
- Gravendyck, M.; Tritt, S.; Spenkoch-Piper, H.; Kaleta, E.F. Antigenic diversity of psittacine herpesviruses: Cluster analysis of antigenic differences obtained from cross-neutralization tests. Avian Pathol. 1996, 25, 345–357. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Reed, L.; Muench, H. A simple method of estimating fifty per cent endpoints. Am. J. Epidemiol. 1938, 27, 493–497. [Google Scholar] [CrossRef]
- Archetti, I.; Horsfall, F.L. Persistent antigenic variation of influenza A viruses after incomplete neutralization in ovo with heterologous immune serum. J. Exp. Med. 1950, 92, 441–462. [Google Scholar] [CrossRef] [PubMed]
- Lwapa, F.E.I.; Masumu, J.M.; Matala, F.M.; Mukoko, F.N.; Mbao, V.; Moula, N.; Antoine-Moussiaux, N.; Isenge, F.L.E.; Masumu, J.; Mfwamba, F.M.; et al. Participatory assessment of paid vaccination campaigns for village chickens against Newcastle disease in Kongo Central province. Prev. Vet. Med. 2019, 172, 104783. [Google Scholar] [CrossRef] [PubMed]
- Young, M.B.; Alders, R.; Grimes, S.; Spradbrow, P.B.; Dias, P.; Silva, A.D.; Lobo, Q. Controlling Newcastle Disease in Village Chickens—A Laboratory Manual; Monographs; Australian Centre for International Agricultural Research: Canberra, Australia, 2002; number 117714; pp. 46–51. [Google Scholar]
- Miller, P.J.; King, D.J.; Afonso, C.L.; Suarez, D.L. Antigenic differences among Newcastle disease virus strains of different genotypes used in vaccine formulation affect viral shedding after a virulent challenge. Vaccine 2007, 25, 7238–7246. [Google Scholar] [CrossRef] [PubMed]
- Cattoli, G.; Fusaro, A.; Monne, I.; Molia, S.; Le Menach, A.; Maregeya, B.; Nchare, A.; Bangana, I.; Maina, A.G.; Koffi, J.-N.N.; et al. Emergence of a new genetic lineage of Newcastle disease virus in West and Central Africa—Implications for diagnosis and control. Vet. Microbiol. 2010, 142, 168–176. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Isolate | Date of Isolation | Host | Location | ICPI | MDT | Cleavage Site Amino Acid Motif | Accession Number |
---|---|---|---|---|---|---|---|
NDV/Ck/DRC/18VIR3696/2018 | May 2018 | Chicken | 0.2843 S 20.8851 E | nd | nd | 112RRQKR|F117 | MW363929 |
NDV/Ck/DRC/PL33/2018 | May 2018 | Chicken | 0.2843 S 20.8851 E | 1.84 | 54.4 | 112RRQKR|F117 | MW363930 |
NDV/Ck/DRC/PL219/2019 | July 2019 | Chicken | −4.2436 S 15.5362 E | 1.92 | 57.2 | 112RRQKR|F117 | MW363931 |
Genotype | Number of Base Substitutions Per Site | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DRC | I | II | III | IV | V | VI | VII | VIII | IX | X | XI | XII | XIII | XIV | XVI | XVII | XVIII | XIX | XX | |
DRC (n = 2) | ||||||||||||||||||||
I (n = 12) | 20.09 | |||||||||||||||||||
II (n = 3) | 21.67 | 14.20 | ||||||||||||||||||
III (n = 3) | 19.30 | 12.79 | 14.66 | |||||||||||||||||
IV (n = 2) | 15.84 | 13.02 | 14.81 | 10.09 | ||||||||||||||||
V (n = 6) | 15.72 | 18.56 | 19.98 | 16.33 | 14.24 | |||||||||||||||
VI (n = 21) | 15.10 | 19.85 | 21.10 | 18.72 | 16.03 | 15.25 | ||||||||||||||
VII (n = 14) | 13.74 | 19.11 | 21.75 | 17.61 | 14.95 | 15.54 | 13.89 | |||||||||||||
VIII (n = 3) | 14.46 | 15.19 | 1.709 | 13.63 | 10.89 | 11.39 | 12.09 | 12.72 | ||||||||||||
IX (n = 3) | 19.22 | 12.16 | 13.12 | 9.36 | 9.53 | 15.81 | 18.04 | 17.22 | 12.72 | |||||||||||
X (n = 4) | 22.56 | 12.55 | 12.07 | 14.11 | 14.07 | 19.60 | 20.95 | 20.27 | 16.54 | 12.81 | ||||||||||
XI (n = 3) | 25.94 | 2153 | 23.24 | 19.43 | 14.76 | 21.38 | 24.24 | 24.69 | 19.74 | 17.62 | 22.44 | |||||||||
XII (n = 6) | 14.89 | 20.33 | 23.40 | 19.15 | 16.58 | 15.56 | 13.77 | 12.45 | 13.36 | 18.71 | 21.37 | 25.65 | ||||||||
XIII (n = 12) | 13.20 | 19.61 | 22.14 | 18.96 | 15.49 | 15.37 | 14.57 | 11.76 | 13.02 | 17.41 | 20.78 | 24.42 | 11.89 | |||||||
XIV (n = 6) | 16.49 | 23.57 | 26.30 | 22.92 | 19.51 | 18.32 | 17.13 | 15.01 | 15.93 | 22.49 | 23.98 | 29.69 | 14.50 | 14.05 | ||||||
XVI (n = 3) | 17.64 | 17.53 | 19.81 | 16.35 | 13.38 | 14.83 | 16.13 | 16.57 | 11.74 | 15.62 | 18.32 | 22.85 | 16.97 | 16.47 | 19.85 | |||||
XVII (n = 3) | 14.29 | 19.52 | 22.99 | 19.20 | 16.54 | 15.98 | 15.84 | 13.58 | 14.30 | 17.78 | 21.64 | 23.91 | 13.08 | 12.46 | 13.59 | 18.08 | ||||
XVIII (n = 6) | 13.82 | 19.84 | 21.98 | 18.57 | 15.74 | 15.50 | 14.05 | 12.65 | 13.25 | 17.60 | 20.86 | 23.87 | 12.00 | 11.57 | 13.74 | 16.97 | 10.92 | |||
XIX (n = 3) | 18.26 | 21.96 | 22.35 | 20.02 | 17.40 | 09.59 | 17.79 | 17.92 | 14.47 | 18.97 | 22.40 | 24.93 | 18.81 | 18.03 | 21.03 | 18.40 | 18.84 | 18.27 | ||
XX (n = 6) | 13.30 | 16.82 | 19.14 | 16.17 | 13.28 | 12.97 | 09.14 | 11.89 | 09.69 | 14.91 | 18.85 | 21.43 | 12.54 | 12.53 | 16.15 | 13.52 | 13.17 | 12.13 | 16.18 | |
XXI (n = 10) | 16.25 | 20.55 | 22.55 | 19.57 | 17.03 | 16.76 | 11.73 | 15.30 | 13.62 | 18.66 | 22.12 | 25.12 | 16.09 | 16.19 | 19.24 | 17.68 | 17.88 | 16.00 | 19.20 | 10.47 |
Virus | Antiserum to Virus a | |||
PL33/18 | PL219/19 | I-2 | B1 | |
NDV/Ck/DRC/PL33/2018 | 1024 | 512 | 256 | 512 |
NDV/Ck/DRC/PL219/2019 | 512 | 512 | 512 | 512 |
I-2 vaccine | 512 | 512 | 512 | 512 |
B1 vaccine | 256 | 1024 | 1024 | 512 |
Virus | Antiserum to Virus b | |||
PL33/18 | PL219/19 | I-2 | B1 | |
NDV/Ck/DRC/PL33/2018 | 1.00 | 1.00 | 0.98 | 0.99 |
NDV/Ck/DRC/PL219/2019 | 0.99 | 1.00 | 0.89 | 0.95 |
I-2 vaccine | 0.98 | 0.98 | 1.00 | 0.97 |
B1 vaccine | 0.90 | 1.00 | 0.99 | 1.00 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Twabela, A.T.; Nguyen, L.T.; Masumu, J.; Mpoyo, P.; Mpiana, S.; Sumbu, J.; Okamatsu, M.; Matsuno, K.; Isoda, N.; Zecchin, B.; et al. A New Variant among Newcastle Disease Viruses Isolated in the Democratic Republic of the Congo in 2018 and 2019. Viruses 2021, 13, 151. https://doi.org/10.3390/v13020151
Twabela AT, Nguyen LT, Masumu J, Mpoyo P, Mpiana S, Sumbu J, Okamatsu M, Matsuno K, Isoda N, Zecchin B, et al. A New Variant among Newcastle Disease Viruses Isolated in the Democratic Republic of the Congo in 2018 and 2019. Viruses. 2021; 13(2):151. https://doi.org/10.3390/v13020151
Chicago/Turabian StyleTwabela, Augustin T., Lam Thanh Nguyen, Justin Masumu, Patrick Mpoyo, Serge Mpiana, Julienne Sumbu, Masatoshi Okamatsu, Keita Matsuno, Norikazu Isoda, Bianca Zecchin, and et al. 2021. "A New Variant among Newcastle Disease Viruses Isolated in the Democratic Republic of the Congo in 2018 and 2019" Viruses 13, no. 2: 151. https://doi.org/10.3390/v13020151
APA StyleTwabela, A. T., Nguyen, L. T., Masumu, J., Mpoyo, P., Mpiana, S., Sumbu, J., Okamatsu, M., Matsuno, K., Isoda, N., Zecchin, B., Monne, I., & Sakoda, Y. (2021). A New Variant among Newcastle Disease Viruses Isolated in the Democratic Republic of the Congo in 2018 and 2019. Viruses, 13(2), 151. https://doi.org/10.3390/v13020151